Understanding Mesothelioma
A rare cancer arising from the mesothelial lining of the chest, abdomen, or heart, most commonly linked to past asbestos exposure.
- Asbestos-associated
- Multiple anatomical sites
- Multimodal treatment
- Most Common In
- Pleura (~80%)
- Key Risk Factor
- Asbestos Exposure
- Typical Onset
- 20–50 Yrs Post-Exposure
- Common Subtype
- Epithelioid
- Advanced Therapies
- Immunotherapy Access
Condition Overview
Mesothelioma is a rare and aggressive cancer that develops in the thin layer of tissue (mesothelium) lining the lungs (pleura), abdomen (peritoneum), or, rarely, the heart (pericardium). It is strongly associated with prior asbestos exposure, often occurring decades after the original exposure.
Types and Subtypes
Mesothelioma is classified by anatomical site and by histologic subtype, both of which influence treatment and prognosis.
Symptoms and Signs
Symptoms vary depending on the site involved and are often nonspecific in early disease.
Causes and Risk Factors
Asbestos exposure is the dominant and best-established risk factor for mesothelioma.
Diagnosis and Investigations
Diagnosis combines imaging, tissue biopsy, and specialized pathology review, as mesothelioma can be difficult to distinguish from other cancers.
Staging and Risk Groups
Pleural mesothelioma is staged using a TNM-based system (Stages I–IV); peritoneal disease is often described by extent of spread rather than formal TNM staging.
Standard Treatment
Treatment is multimodal where possible, combining surgery, chemotherapy, and sometimes radiation, tailored to stage, subtype, and overall fitness.
Advanced & Emerging Therapies
Immunotherapy has changed the treatment landscape for mesothelioma, and several other approaches are under active investigation.
Immunotherapy
Nivolumab plus Ipilimumab
A dual checkpoint inhibitor combination approved as a first-line option for unresectable malignant pleural mesothelioma.
Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
Cytoreductive Surgery with HIPEC
Used in selected peritoneal mesothelioma cases at specialized centers.
Cellular Therapy
Mesothelin-Targeted CAR-T and TIL Approaches
Investigational cellular therapies targeting mesothelin-expressing tumor cells are being studied in clinical trials.
Antibody-Drug Conjugate
Mesothelin-Targeted ADCs
Emerging agents in trials aiming to deliver chemotherapy directly to mesothelin-expressing tumors.
Biomarkers & Precision Medicine
Pathologic and molecular markers help confirm diagnosis and may guide treatment selection.
When to Seek a Second Opinion
Because mesothelioma is rare and treatment approaches vary widely by center experience, a second opinion is often valuable.
Clinical Trials & Research
Prognosis & Outcomes
Prognosis varies considerably based on histologic subtype, stage at diagnosis, and treatment eligibility.
Supportive Care
Supportive care plays a major role in managing symptoms and improving quality of life throughout treatment.
How CancerFax Helps You Explore Treatment Options
CancerFax helps mesothelioma patients get expert thoracic oncology review of imaging and pathology, connect with specialists experienced in surgery and HIPEC, and explore immunotherapy and clinical trial access.
Get a free case reviewFrequently Asked Questions
Mesothelioma is a rare cancer that develops in the lining of the lungs, abdomen, or heart, most often caused by past asbestos exposure.
Common early signs include shortness of breath, chest pain, persistent cough, or abdominal swelling, depending on the site affected.
Most cases are linked to asbestos exposure, though a small proportion occur without a clear exposure history, sometimes related to genetic factors such as BAP1 mutations.
It typically develops 20 to 50 years after exposure, which is why a detailed occupational history is important for diagnosis.
Diagnosis involves imaging studies, fluid analysis, and a tissue biopsy reviewed with specialized pathology testing to confirm the diagnosis and subtype.
Treatment may include surgery, chemotherapy, immunotherapy, and radiation, often combined, depending on stage, subtype, and overall fitness.
Surgery is only an option for a subset of patients with localized disease and adequate fitness; eligibility should be assessed at an experienced thoracic oncology center.
Immunotherapy combinations are now a standard first-line option for many patients with unresectable pleural mesothelioma and have improved outcomes for some patients.
Yes, trials exploring cellular therapies, antibody-drug conjugates, and novel immunotherapy combinations are ongoing at specialized centers.
Yes. CancerFax can help review your imaging and pathology reports, coordinate a second opinion with thoracic oncology specialists, and explore advanced therapy or clinical trial access, including international coordination where relevant.
Get Expert Guidance on Your Diagnosis
Share your reports for a structured review and explore second opinion and advanced therapy options.